stockrowAMNEAL PHARMACEUTICALS, INC.
AMRX Healthcare Drug Manufacturers Specialty & Generic
AMNEAL PHARMACEUTICALS, INC.’s revenue for fiscal 2025 (year ended December 2025) was $3.0 billion, up 8.05% from fiscal 2024.
- Revenue
- +9.96%
- EPS
- +267.0%
- Free cash flow
- −50.9%
- Total debt
- +23.8%
Quarter to September 2026, against a year earlier
Follow AMRX
Alert me
AMNEAL PHARMACEUTICALS, INC. (AMRX) Return on assets
AMNEAL PHARMACEUTICALS, INC.'s return on assets over the twelve months to 30 September 2026 was 3.01%, up 1.0 percentage points from fiscal 2025 (2.01%). Over the past ten years it has ranged from −9.03% (fiscal 2019) to 2.60% (fiscal 2015); the current reading is higher than 82% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of −1.67% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | 2.01% | 5.36 |
| FY2024 | −3.35% | (1.04) |
| FY2023 | −2.31% | 1.05 |
| FY2022 | −3.36% | (3.63) |
| FY2021 | 0.27% | (2.10) |
| FY2020 | 2.37% | 11.40 |
| FY2019 | −9.03% | (8.30) |
| FY2018 | −0.73% | (0.73) |
| FY2017 | 0.00% | 0.00 |
| FY2016 | 0.00% | (2.60) |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| LQDA Liquidia Corporation compare | 35.6% |
| SUPN Indivior Pharmaceuticals Inc. compare | 32.8% |
| KNSA Kiniksa Pharmaceuticals International, plc compare | 12.9% |
| LNTH Lantheus Holdings, Inc. compare | 11.4% |
| RDY Dr. Reddy's Laboratories Ltd compare | 4.44% |
| AMRX AMNEAL PHARMACEUTICALS, INC. | 3.01% |
| ALKS Alkermes plc compare | −0.01% |
| ELAN Elanco Animal Health Incorporated compare | −1.46% |
| HIMS Hims & Hers Health, Inc. compare | −5.16% |
| Drug Manufacturers Specialty & Generic industry median | −1.67% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on AMRX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement